AUS
NZ
UK
CA
USA
IND
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ:UTHR), exercised 9,500 stock options and sold a total of 8,577 shares on July 24, 2026, as disclosed in a filing with the Securities and Exchange Commission. These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted in November 2025, with share sale prices ranging from approximately $528 to $535 per share. This activity represents a routine portfolio rebalancing by the company's chief executive.
Key Points
- NASDAQ: UTHR
- CEO Martine Rothblatt exercised 9,500 stock options at $135.42 per share on July 24, 2026
- Rothblatt sold 8,577 shares in multiple transactions at weighted average prices between $528.72 and $535.03 per share on the same day
- All trades were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025, set to continue through December 31, 2026, or until 1,734,410 options are exercised
- Post-transactions, Rothblatt retains indirect beneficial ownership of 324,443 shares held via family trusts
CEO Martine Rothblatt Executes Stock Option Exercise and Coordinated Share Sales
On July 24, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation, exercised 9,500 stock options at an exercise price of $135.42 per share, per the company's SEC disclosure. These options, expiring March 15, 2027, were exercised pursuant to a pre-arranged Rule 10b5-1(c) trading plan. The exercise resulted in Rothblatt acquiring 9,500 shares of common stock.
That same day, Rothblatt completed eight coordinated share sale transactions totaling 8,577 shares. The weighted average sale prices ranged from $528.72 to $535.03 per share, with individual trades executed at slightly varying prices throughout the trading session. The filing notes that Rothblatt will provide detailed transaction data upon request to the SEC, the issuer, or company security holders.
Details of the Pre-Arranged Rule 10b5-1 Trading Plan
All July 24, 2026, transactions were conducted under a Rule 10b5-1 trading plan adopted by Rothblatt on November 7, 2025. This SEC rule allows insiders to establish predetermined trading plans that provide an affirmative defense against insider trading allegations. The plan is scheduled to remain in effect until either December 31, 2026, or until Rothblatt exercises a total of 1,734,410 stock options expiring March 15, 2027.
This structured approach facilitates systematic portfolio diversification and liquidity management by the CEO, enabling orderly sales without concerns about material nonpublic information.
Post-Transaction Beneficial Ownership Structure
Following the July 24 transactions, Rothblatt retains significant indirect beneficial ownership of United Therapeutics shares through family trust arrangements. The filing indicates Rothblatt holds 324,443 shares indirectly via trusts where Rothblatt shares investment power and is a beneficiary. Additionally, Rothblatt directly owns 40,513 shares and indirectly owns 249,108 shares held in family trusts managed by Rothblatt’s spouse as sole trustee or co-trustee with revocation power.
Rothblatt's spouse also holds 166 shares indirectly through trusts and 45,596 shares through other trust structures. Rothblatt maintains beneficial ownership of 8,902 shares through trusts where Rothblatt serves as sole trustee and beneficiary or co-trustee with revocation authority. Collectively, these holdings demonstrate substantial ongoing equity participation by the CEO.
Stock Option Holdings and Expiration Details
The filing reveals Rothblatt retains 274,910 stock options indirectly held via family trusts, providing significant upside exposure to United Therapeutics stock price appreciation before their March 15, 2027 expiration. The trading plan contemplates exercising up to 1,734,410 options by December 31, 2026, underscoring investor interest in monitoring ongoing option exercises and share sales under this schedule.
The options exercised on July 24 carried an exercise price of $135.42, substantially below the contemporaneous share sale prices, reflecting notable stock appreciation.
Weighted Average Share Sale Execution and Pricing
The filing details eight separate share sale transactions on July 24, 2026, each reported with weighted average prices. The initial sale involved 820 shares at $528.72 per share, with individual trades ranging from $528.16 to $528.83. The second sale included 2,285 shares at a weighted average of $530.45, with trades between $529.71 and $530.70.
Subsequent sales reflected market conditions throughout the day: 1,115 shares at $531.10, 2,719 shares at $532.27, 1,818 shares at $533.20, 630 shares at $534.39, and 113 shares at $535.03. This staggered approach likely allowed the market to absorb sales without significant price impact while capturing incremental price gains.
Trust Structures and Indirect Ownership Details
The disclosure categorizes Rothblatt’s indirect beneficial ownership through various family trust structures. Many shares are held in trusts where Rothblatt shares investment power and is a beneficiary, reflecting discretionary investment authority among family members. Additional shares are held in trusts managed by Rothblatt’s spouse as sole trustee and beneficiary or as co-trustee with revocation power, indicating estate planning strategies involving spousal involvement.
Rothblatt also holds shares in trusts where Rothblatt serves as sole trustee and beneficiary or co-trustee with revocation authority. These sophisticated estate planning structures are common among senior executives for managing equity ownership.
Regulatory Compliance and Filing Certification
The filing, executed on July 27, 2026, by John S. Hess, Jr. under a power of attorney from Rothblatt, includes standard SEC certifications affirming the accuracy and completeness of the disclosure. The power of attorney permits Hess to file required documents on behalf of the CEO, a typical administrative practice.
The transactions comply with Section 16(a) of the Securities Exchange Act of 1934, requiring insiders to report securities transactions. The filing confirms the trades were made pursuant to a written Rule 10b5-1(c) plan, providing regulatory authorization and mitigating concerns about trading on material nonpublic information.
Market Context and Executive Liquidity Management
The July 24, 2026, transactions generated approximately $4.56 million in proceeds from the sale of 8,577 shares, reflecting a deliberate liquidity and diversification strategy by Rothblatt. The pre-arranged trading plan, established in November 2025 and continuing through 2026, facilitates orderly disposition of equity compensation.
Exercising options at $135.42 and selling shares at roughly three to four times that price highlights significant stock appreciation. The progressive sales throughout the trading day, with improving prices, demonstrate an execution strategy designed to optimize sale prices while managing volume.
Ongoing Trading Plan and Timeline Through Year-End 2026
The Rule 10b5-1 trading plan remains active until December 31, 2026, or until Rothblatt exercises 1,734,410 options, whichever comes first. This plan anticipates continued option exercises and share sales, with future insider transaction disclosures expected. Investors can monitor progress via periodic Form 4 filings.
The March 15, 2027 expiration of the options establishes a deadline for exercising remaining options, as unexercised options will expire worthless. The plan’s December 31, 2026 termination ensures most transactions conclude before year-end, allowing Rothblatt to secure liquidity and pricing ahead of the final quarter. This timeline clarifies the expected duration and scope of the CEO’s equity diversification activities.
